Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CEO Joel Lewis sold 56,000 shares of Galectin Therapeutics stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.89, for a total value of $49,840.00. Following the completion of the transaction, the chief executive officer now directly owns 897,012 shares in the company, valued at approximately $798,340.68. This represents a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Galectin Therapeutics Price Performance
Shares of Galectin Therapeutics stock traded up $0.03 during trading on Thursday, reaching $0.87. 1,032,216 shares of the company traded hands, compared to its average volume of 241,998. The firm has a market capitalization of $54.61 million, a PE ratio of -1.19 and a beta of 0.69. The company has a 50 day moving average price of $2.37 and a 200-day moving average price of $2.44. Galectin Therapeutics Inc. has a 1-year low of $0.73 and a 1-year high of $4.27.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on GALT. StockNews.com raised shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. HC Wainwright restated a "buy" rating and set a $11.00 target price on shares of Galectin Therapeutics in a research report on Friday, November 15th.
Get Our Latest Stock Report on GALT
Hedge Funds Weigh In On Galectin Therapeutics
Several institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in Galectin Therapeutics during the 2nd quarter valued at $43,000. Rhumbline Advisers bought a new stake in shares of Galectin Therapeutics during the second quarter worth about $44,000. Gladstone Institutional Advisory LLC bought a new stake in shares of Galectin Therapeutics during the third quarter worth about $60,000. Barclays PLC raised its holdings in shares of Galectin Therapeutics by 309.0% in the 3rd quarter. Barclays PLC now owns 28,587 shares of the company's stock worth $79,000 after acquiring an additional 21,598 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Galectin Therapeutics by 161.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,628 shares of the company's stock valued at $84,000 after acquiring an additional 18,907 shares in the last quarter. Institutional investors and hedge funds own 11.68% of the company's stock.
Galectin Therapeutics Company Profile
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Featured Articles
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
